Our breakthrough opti-ox™ technology combines synthetic and stem cell biology for the precise, efficient and consistent reprogramming of stem cells.
Location: United Kingdom
Employees: 51-200
Total raised: $224.57M
Founded date: 2016
Investors 7
Funding Rounds 4
| Date | Series | Amount | Investors |
| 12.01.2026 | Series C | $50M | - |
| 19.12.2024 | - | $30M | M&G In... |
| 05.11.2021 | Series B | $103.07M | - |
| 16.06.2020 | Series A | $41.5M | - |
Mentions in press and media 24
| Date | Title | Description |
| 14.01.2026 | Biotech Innovator bit.bio Secures $50M to Revolutionize Drug Discovery | bit.bio, a pioneering UK biotech, has secured $50 million in Series C funding, led by M&G Investments. This significant capital infusion will supercharge its human cell programming technology. The company aims to accelerate drug discove... |
| 13.01.2026 | Hadrian Secures $1.6 Billion: Powering U.S. Industrial Future | Hadrian, a leader in automated aerospace and defense manufacturing, just secured $1.6 billion in funding. This capital boosts its valuation to $1.6 billion. T. Rowe Price led the round. The company will expand U.S. factory operations. It ai... |
| 12.01.2026 | bit.bio Raises $50M in Funding | bit.bio, a Cambridge, UK-based biotech company leveraging human cell programming technology, raised $50M in funding. The round was led by M&G Investments. The company intends to use the funds to accelerate the development of, and access... |
| 12.01.2026 | Hadrian Raises Funding at $1.6 Billion Valuation | Hadrian, a Los Angeles, California-based developer of automated factories for aerospace and defense, raised expanded capital at a $1.6 billion valuation. The round wasled by T. Rowe Price Associates, Inc. with participation from Altimeter C... |
| 11.01.2026 | bit.bio Raises $50 Million Series C Led by M&G To Scale Human Cell Programming Platform | M&G Investments has led a $50 million Series C funding round for bit.bio, a Cambridge-based biotechnology company developing human cell programming technology to improve the speed and predictability of drug discovery and safety testing.... |
| 19.12.2024 | bit.bio raises $30 Million led by M&G Investments | bit.bio raises $30 Million led by M&G Investments to focus on tools for the research, drug discovery and cell therapy markets. Jonathan Milner appointed Interim CEO; Mark Kotter assumes Vice Chairman role as Company expands Board with d... |
| 06.08.2024 | bit.bio expand Executive Team with appointment of Przemek Obloj as Chief Financial Officer | Cambridge, UK – bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, announces the appointment of Przemek Obloj as Chief Financial Officer. Mr. Obloj will oversee the company’s financial s... |
| 29.07.2024 | Cultivated meat is down but not out, says meat industry veteran and new CEO at Meatable | Cultivated meat may be down, but it’s not out, insists the new US-based CEO of Dutch startup Meatable. The reason is simple, claims Jeff “Trip” Tripician, a meat industry veteran who took the helm of the company last month. “Our supply chai... |
| 28.03.2024 | Meatable CTO on the cultivated meat industry cycle: ‘Hype, stagnation, consolidation, redirection’ | Dutch startup Meatable has slashed production times for cultivated pork in recent months by dramatically speeding up the process by which its stem cells differentiate into fat and muscle, further improving its unit economics at a time when ... |
| 07.08.2023 | Dutch cultivated meat startup Meatable raises $35m Series B, gears up for market entry in 2024 | Dutch cultivated meat startup Meatable has raised $35 million in a series B round led by Agronomics, taking its total funding to $95 million as it gears up to launch pork sausages and dumplings in Singapore next year. The round includes $17... |
Show more